This article was originally published in The Gray Sheet
Pre-merger licensing pact allows firms to move ahead with platform integration, giving IsoTis access to GenSci technology related to its demineralized bone matrix reverse-phase medium (RPM) carrier system. IsoTis will combine the RPM carrier system with its lead OsSatura synthetic bone substitute technology for dental and maxillofacial reconstruction. A June 3 merger deal is expected to close this fall (1"The Gray Sheet" June 9, 2003, p. 26)...
You may also be interested in...
IsoTis will continue to develop its Allox allogenic growth factor spray for chronic wound treatment, while directing the majority of its R&D at osteobiologics
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.